
Pharmaceutical companies Mylan NV, Pfizer, and other pharmaceutical companies lost their bid to end antitrust litigation brought by nearly every state attorney general over an alleged industrywide scheme to inflate the cost of generic dermatology products, reported Bloomberg.
The ruling by US District Judge Claire Cecchi in Newark, New Jersey, means the companies must face claims they violated state laws by secretly agreeing not to compete to sell drugs used to treat acne, psoriasis, and other conditions.
The attorney generals accused the companies of conspiring to keep prices for the drugs artificially high. They said the companies agreed to divide the market among themselves and not compete on price.
Related: UK Fines Big Pharma Over Drug Prices
The lawsuit was first filed back in April 2016 and arises out of an alleged price-fixing conspiracy by the defendants, which include numerous major pharmaceutical companies such as Mylan, Pfizer, and Teva Pharmaceuticals, along with individual executives of the companies.
The lawsuit was filed on behalf of the attorney general of the states of Arizona, Connecticut, Idaho, Illinois, Iowa, Kansas, Maine, Maryland, Massachusetts, Minnesota, Nevada, New Mexico, North Dakota, Oregon, Rhode Island and Vermont, as well as the District of Columbia.
The lawsuit claims that the defendants conspired to fix prices, allocate customers, and engage in other anticompetitive conduct in relation to generic dermatology drugs. The lawsuit is seeking to recover the damages which were caused by the alleged illegal activities.
Featured News
Senators Urged to Expedite Gail Slater’s Confirmation as DOJ Antitrust Chief
Feb 11, 2025 by
CPI
Former Michigan Asphalt Executive Pleads Guilty in Bid-Rigging Scheme
Feb 11, 2025 by
CPI
Ballard Spahr Expands Litigation Team with Addition of Antitrust Attorney in Seattle
Feb 11, 2025 by
CPI
Portuguese Court Overturns €225 Million Fine for Banking Collusion Due to Statute of Limitations
Feb 11, 2025 by
CPI
Binance and SEC Request Stay in Crypto Lawsuit Amid New Regulatory Task Force
Feb 11, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon